Open access · OA
via Europe PMC
Nicotinamide Mononucleotide Adenylyltransferase 1 and NAD<sup>+</sup> Homeostasis in Neuroprotection and Aging.
Metabolites · 2026
Genomic instability
Epigenetic alterations
Loss of proteostasis
Altered intercellular communication
Chronic inflammation
Human
Drosophila
Preclinical / animal
Review
Abstract
Nicotinamide adenine dinucleotide (NAD<sup>+</sup>) is a fundamental metabolic cofactor and signaling molecule that supports redox reactions, DNA repair, chromatin regulation, stress adaptation, inflammation, and neuronal maintenance. Age-associated NAD<sup>+</sup> decline has been implicated in brain aging and neurodegenerative disorders, but the causal node and limiting compartment differ across tissues and disease states. Nicotinamide mononucleotide adenylyltransferase 1 (NMNAT-1) catalyzes the final step in NAD<sup>+</sup> biosynthesis and represents the major nuclear isoform of the mammalian NMNAT family. Direct human genetic evidence establishes NMNAT-1 as a causal gene in inherited retinal degeneration, whereas evidence linking endogenous NMNAT-1 to broader brain aging or sporadic neurodegeneration is mainly convergent preclinical, preliminary, or indirect. Beyond NAD<sup>+</sup> synthesis, biochemical and Drosophila studies suggest possible chaperone-like and proteostasis(definition)-supporting functions, but a separable NAD<sup>+</sup>-independent function of endogenous mammalian NMNAT-1 has not yet been established in vivo. Here, we review the molecular structure, localization, and regulation of NMNAT-1, emphasizing calibrated distinctions among catalytic nuclear NAD<sup>+</sup> supply, engineered axonal protection, pathway-adjacent NAD<sup>+</sup> interventions, and putative non-catalytic protection. We further discuss how NMNAT-1 dysfunction may contribute to aging-associated genomic instability, neuroinflammation, synaptic impairment, retinal degeneration, selected neurodegenerative models, and glioma biology. Finally, we evaluate therapeutic strategies targeting NMNAT-1 and NAD<sup>+</sup> pathways, noting that no human trial has yet established efficacy for an NMNAT-1-directed neurological therapy. A compartment-aware and evidence-stratified view is therefore essential for translating NMNAT-1 biology into interventions for age-related neural disease.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.3390/metabo16080597
- Canonical
- link ↗
- Fetched
- 2026-10-07 MST
Cite this
APA
Y, S., B, L., & Z., Q. (2026). Nicotinamide Mononucleotide Adenylyltransferase 1 and NAD<sup>+</sup> Homeostasis in Neuroprotection and Aging. <em>Metabolites</em>. https://doi.org/10.3390/metabo16080597
Vancouver
Y S, B L, Z. Q. Nicotinamide Mononucleotide Adenylyltransferase 1 and NAD<sup>+</sup> Homeostasis in Neuroprotection and Aging. Metabolites. 2026. doi:10.3390/metabo16080597.
BibTeX
@article{sun2026Nicoti,
title = {Nicotinamide Mononucleotide Adenylyltransferase 1 and NAD<sup>+</sup> Homeostasis in Neuroprotection and Aging.},
author = {Sun Y and Li B and Qian Z.},
journal = {Metabolites},
year = {2026},
doi = {10.3390/metabo16080597},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Metabolites 2026
Open access · CC-BY
Nicotinamide Mononucleotide Adenylyltransferase 1 and NAD+ Homeostasis in Neuroprotection and Aging
Alzheimer's & dementia : the journal of the Alzheimer's Association 2026
Open access · OA
NAD<sup>+</sup>‒circadian rhythm coupling in dementia.
Metabolites 2026
Open access · OA
Targeting NAD Homeostasis: Compartmentalization, Quantification, and Modulation.
Trends in neurosciences 2026
Citation only
Epigenetic noise in the aging brain: tuning neuronal vulnerability to neurodegeneration.
IBRO neuroscience reports 2026
Open access · OA
Neuroprotective roles of Klotho signaling in Huntington's disease: From molecular insights to clinical translation.
Life 2025
Open access · CC-BY